Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc. 康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING; AND

ELECTION OF NON-EXECUTIVE DIRECTOR OF THIRD SESSION OF BOARD OF DIRECTORS

POLL RESULTS OF THE AGM

The Board hereby announces the poll results in respect of the resolutions proposed at the AGM on Thursday, June 27, 2024. All resolutions were duly passed by way of poll at the AGM.

ELECTION OF NON-EXECUTIVE DIRECTOR OF THIRD SESSION OF BOARD OF DIRECTORS

At the AGM, Mr. Chi Shing LI (李志成) was elected as non-executive Director of the third session of the Board of Directors.

CanSino Biologics Inc. (the "**Company**") announces that at its 2023 annual general meeting (the "**AGM**") held on Thursday, June 27, 2024, all resolutions proposed were duly passed by way of poll. Resolution No. 1 was voted by cumulative voting. The AGM was convened by the board (the "**Board**") of directors (the "**Directors**") of the Company.

Further details of the resolutions are set out in the notice of the AGM dated June 5, 2024 (the "Notice") and the circular of the Company dated the same date (the "Circular").

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

ATTENDANCE AT THE AGM

The Board is pleased to announce that the AGM was held at No. 1, Yuebin Hall, 2nd Floor, Hyatt Regency Tianjin East, No. 126 Weiguo Road, Hedong District, Tianjin, the PRC, at 1:30 p.m. on Thursday, June 27, 2024.

All Directors, supervisors and senior management of the Company attended the AGM either in person or by means of telecommunication.

The attendance of the AGM is as follows:

	Number of		
	Shares in issue		
	(and entitling		
	holders to		
	attend and	Number of	
	vote for or	Shares present	
	against any	(in person or	Approximate
Class of Shares	resolution)	by proxy)	%
H Shares	132,670,900	38,637,823	29.12%
A Shares	114,372,901(1)	46,071,598	40.28%
Total	247,043,801_	84,709,421	34.29%

Note:

(1) The total number of A Shares for calculating the attendance of the AGM does not include 406,098 A Shares repurchased and deposited in the share repurchase account of the Company as of the date of this announcement.

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the AGM as set out in Rule 13.40 of the Hong Kong Listing Rules; (2) no Shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the AGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

POLL RESULTS OF THE AGM

The poll results of the AGM were as follows:

Ordinary Resolutions (by adopting cumulative voting) ⁽¹⁾		Number of votes and the percentage of number of votes in number of shares in present carrying voting rights (%)			Elected or not ⁽⁴⁾
1.	To consider and approve the election of non-executive Director of	The Resolu	mulative voting:		
	the third session of the Board of Directors.	84,343,853 (99.5684%)			Yes
	Ordinary Resolutions ⁽¹⁾	For ⁽²⁾	Against ⁽²⁾	Abstain ⁽²⁾	Passed by Shareholders ⁽³⁾
2.	To consider and approve the report of the board of directors of the Company for the year of 2023.	84,589,518 (99.8587%)	116,703 (0.1378%)	3,000 (0.0035%)	Yes
3.	To consider and approve the report of the board of supervisors of the Company for the year of 2023.	84,589,518 (99.8587%)	97,603 (0.1152%)	22,100 (0.0261%)	Yes
4.	To consider and approve the annual report of the Company and its subsidiaries for the year of 2023 and its abstract.	84,591,118 (99.8606%)	96,003 (0.1133%)	22,100 (0.0261%)	Yes
5.	To consider and approve the financial accounts report and financial audit report of the Company and its subsidiaries for the year of 2023.	84,610,218 (99.8831%)	96,003 (0.1133%)	3,000 (0.0035%)	Yes
6.	To consider and approve the profit distribution plan of the Company for the year of 2023.	84,591,118 (99.8606%)	115,103 (0.1359%)	3,000 (0.0035%)	Yes
7.	To consider and approve the re-appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP as the domestic auditor and internal control audit agency and the re-appointment of Deloitte Touche Tohmatsu as the international auditor of the Company for the year of 2024.	84,607,019 (99.8793%)	99,202 (0.1171%)	3,000 (0.0035%)	Yes
8.	To consider and approve the proposed increase and/or renewal of bank credit line for the year of 2024.	84,336,035 (99.5595%)	370,186 (0.4370%)	3,000 (0.0035%)	Yes
9.	To consider and approve the proposal on the uncovered deficit amounting to one-third of the total paid-up share capital of the Company.	84,583,642 (99.8518%)	122,574 (0.1447%)	3,005 (0.0035%)	Yes

Special Resolutions ⁽¹⁾		For ⁽²⁾	Against ⁽²⁾	Abstain ⁽²⁾	Passed by Shareholders ⁽³⁾
10.	To consider and approve the proposed amendments to the shareholders' dividend and return plan of the Company for the three years (2023–2025).	84,632,915 (99.9097%)	73,501 (0.0868%)	3,005 (0.0035%)	Yes
11.	To consider and approve the proposed grant of General Mandate to the Board to issue, allot and deal with additional A Shares and/or H Shares (including any sale or transfer of Treasury H Shares of the Company) or equivalent rights not exceeding 20% of the total number of Shares (excluding Treasury H Shares, if any) in issue as of the date of passing this proposed resolution, and to authorize the Board and its delegates to make amendments to the Articles of Association as it thinks fit so as to reflect the new share capital structure upon the issue or allotment of additional shares of the Company pursuant to the General Mandate.	81,578,409 (96.3040%)	3,127,812 (3.6924%)	3,000 (0.0035%)	Yes
12.	To consider and approve the proposed grant of the General Mandate under Simplified Procedure to the Board to issue A Shares.	84,346,387 (99.5717%)	359,834 (0.4248%)	3,000 (0.0035%)	Yes
13.	To consider and approve the proposed grant of the Repurchase Mandate to the Board to repurchase a total number of A Shares and/ or H Shares not exceeding 10% of the number of Shares in issue (excluding Treasury H Shares, if any) as of the date of passing this proposed resolution at the AGM with its own funds.	84,656,590 (99.9379%)	49,631 (0.0586%)	3,000 (0.0035%)	Yes
14.	To consider and approve the proposed authorization for issue of onshore and offshore debt financing instruments.	79,677,576 (94.0601%)	5,028,645 (5.9364%)	3,000 (0.0035%)	Yes

Notes:

- (1) Please refer to the Notices and Circular for details of these resolutions.
- (2) All percentages rounded to four decimal places. The percentage figures included in this table have been subject to rounding adjustments.
- (3) An ordinary resolution is passed by more than half of votes casted in favor of it, and a special resolution is passed by more than two-thirds of the votes casted in favor of it.
- (4) According to the Articles of Association of the Company, cumulative voting system was adopted in respect of the above Resolution No. 1. A candidate for Director is elected when the number of votes in favor obtained by such candidate exceeds half of the total number of shares carrying voting rights held by those who attended the AGM in person or by proxies.

ELECTION OF NON-EXECUTIVE DIRECTOR OF THIRD SESSION OF BOARD OF DIRECTORS

At the AGM, Mr. Chi Shing LI (李志成) was elected as non-executive Director of the third session of the Board of Directors.

Mr. Li's term of office shall come into effect immediately after conclusion of the AGM and until the expiry of the term of the third session of the Board. For details of Mr. Li's biography and the determination of his remuneration, please refer to the Circular. As of the date of this announcement, there was no change in such information.

SCRUTINEERS

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM. Two representatives of the Shareholders, two lawyers of Jingtian & Gongcheng Law Firm, and one Supervisor participated in the scrutiny of the poll results.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, June 27, 2024

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU, and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.